Shanghai Clinical Cohort - Adrenal Disease
ConditionAdrenal Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorShanghai Jiao Tong University School of Medicine
About this trial
As a vital organ responsible for producing life-sustaining hormones, the adrenal gland is associated with a wide range of diseases. These diseases affect multiple systems throughout the body and carry a high rate of mortality and disability. Current diagnosis and treatment face several challenges: significant variability in hormone testing results, inaccurate localization via imaging techniques, unclear molecular characteristics of adrenal tumors, and difficulty in determining prognosis through pathology. Therefore, establishing a clinical research cohort for adrenal diseases is essential. Such a cohort will enable in-depth exploration of disease mechanisms, identification of disease subtypes, optimization of diagnostic criteria, evaluation of treatment efficacy, advancement of personalized medicine, and formulation of prevention and treatment strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
A signed and dated informed consent form
Commitment to abide by the study procedures and cooperate with the implementation of the entire study process
Patients diagnosed with adrenal diseases, including aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, and congenital adrenal hyperplasia; regardless of whether they have received adrenal surgery, radiotherapy, and/or medication therapy
Aged between 18 and 75 years
Disqualifiers
Refuse to sign the informed consent form
Patients without adrenal diseases
Have specified diseases or conditions (physical or psychological, identified through physical examination) that warrant exclusion from the study
Trial population
Aged between 18 and 75 years; diagnosed with adrenal diseases, including primary aldosteronism, pheochromocytoma, Cushing's syndrome, congenital adrenal hyperplasia, adrenocortical carcinoma, etc.; in stable condition, capable of tolerating all examinations and follow-ups required by the study. These patients receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.
Other interventionReceive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.
Treatment groups
600 Participants
are divided into 1 treatment groupGroup A: Adrenal cohort1 intervention
Trial outcomes
Primary outcomes
1
Post-Treatment Remission Rate
Time frame
at least six months or more2
Treatment Response Rate
Time frame
at least six months or moreSponsors and contacts
Click on the lead sponsor to view all of their trials.
Shanghai Jiao Tong University School of Medicine
Lead sponsor
Ruijin Hospital
Sponsor institution
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Collaborator
RenJi Hospital
Collaborator
Shanghai Zhongshan Hospital
Collaborator
Shanghai Public Health Clinical Center
Collaborator
Source ClinicalTrials.gov